Gender-Affirming Care — MCQs

Q: A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?

Completion of pubertal development makes GnRH analogs ineffective. ***Completion of pubertal development makes GnRH analogs ineffective*** - **GnRH analogs** are primarily used to suppress the progression of endogenous puberty; once a patient has reached **Tanner stage 5**, biological puberty is complete, rendering suppression redundant. - At this physiological stage, initiating **cross-sex hormones** (gender-affirming hormone therapy) is the appropriate clinical step to align physical characteristics with gender identity. *Parental consent is available* - While **parental consent** is a legal and ethical requirement for treating minors, it does not dictate the physiological choice between suppression and hormone therapy. - Consent is necessary for either **GnRH analogs** or **cross-sex hormones**, but the patient's **Tanner stage** is the medical deciding factor here. *Mental health evaluation shows no contraindications* - A thorough **mental health evaluation** is a prerequisite for all gender-affirming medical interventions to ensure the diagnosis of **gender dysphoria**. - While it confirms readiness for treatment, it does not differentiate which specific endocrine intervention is biologically appropriate for a **Tanner 5** adolescent. *Patient expresses strong desire for rapid physical changes* - **Patient autonomy** and goals are vital, but clinical protocols prioritize developmental staging over the desired speed of changes to ensure safety. - Although **cross-sex hormones** do produce rapid changes compared to analogs, the medical rationale for skipping analogs is the **completion of puberty**, not patient preference.

Q: A 35-year-old transgender woman desires fertility preservation before starting feminizing hormone therapy. She has limited financial resources. Which option provides the best balance of efficacy, cost, and time efficiency?

Sperm banking before hormone initiation. ***Sperm banking before hormone initiation*** - **Sperm banking** is the gold standard for fertility preservation as it is the most **cost-effective**, non-invasive, and proven method for transgender women. - It should be performed **before** starting feminizing therapy because hormones like **estrogen** and **anti-androgens** suppress the HPG axis and severely impair **spermatogenesis**. *Testicular tissue cryopreservation* - This is currently considered an **experimental technique** and is not standard clinical practice for adult fertility preservation. - It is significantly more **expensive** and requires an invasive surgical procedure (testicular biopsy) compared to simple masturbation for sperm banking. *Delaying hormone therapy until natural conception* - This is often not a viable or desirable option for many patients due to the high risk of worsening **gender dysphoria** during the delay period. - It assumes the patient currently has a partner with whom they can conceive naturally and does not address **long-term fertility** needs. *Sperm extraction after 6 months of hormone therapy* - After 6 months of hormone therapy, **testicular atrophy** and **azoospermia** are common, making extraction via **TESE** much less likely to be successful. - To attempt this, the patient would likely need to **discontinue hormone therapy** for months, leading to a return of secondary masculine characteristics and significant psychological distress.

Q: A 28-year-old transgender man presents 6 months after initiating testosterone therapy with persistent vaginal bleeding despite amenorrhea for 4 months. Labs show testosterone 650 ng/dL and hemoglobin 9.2 g/dL. What is the most appropriate next step?

Perform transvaginal ultrasound and endometrial sampling. ***Perform transvaginal ultrasound and endometrial sampling*** - Unexpected **vaginal bleeding** after achieving amenorrhea in a transgender man requires investigation to rule out **endometrial hyperplasia** or malignancy. - Although testosterone causes vaginal atrophy, it can also be **aromatized into estrogen**, potentially leading to endometrial proliferation; investigation is warranted given the significant **anemia**. *Add progestin therapy* - While progestins are used to stop heavy bleeding, they should not be started before a **diagnostic evaluation** of the endometrium has been performed in this context. - Adding progestin without a diagnosis could mask **underlying pathology** like malignancy or structural abnormalities. *Increase testosterone dose* - The patient's testosterone level (650 ng/dL) is already within the **physiologic male range** (300-1000 ng/dL). - Increasing the dose may lead to higher rates of **aromatization to estrogen**, potentially worsening the endometrial issues rather than stopping the bleeding. *Discontinue testosterone and observe* - Discontinuing gender-affirming therapy can cause significant **psychological distress** and is not the standard first step for investigating bleeding. - Observation is inappropriate here because the patient is **anemic** and requires an active diagnostic workup to identify the source of blood loss.

Q: A 19-year-old transgender woman on feminizing hormone therapy presents with galactorrhea and serum prolactin of 85 ng/mL (normal <25). Which component of her therapy is most likely responsible?

Cyproterone acetate. ***Cyproterone acetate*** - **Cyproterone acetate** is a potent **progestogen** and anti-androgen that can cause **hyperprolactinemia** by exerting a **dopamine-antagonistic** effect or stimulating lactotroph hyperplasia. - It is a well-documented cause of **galactorrhea** and significant prolactin elevation in transgender individuals receiving feminizing therapy. *Finasteride* - **Finasteride** is a **5-alpha reductase inhibitor** that prevents the conversion of testosterone to dihydrotestosterone (DHT) and does not significantly impact **prolactin** levels. - Its primary side effects relate to **sexual dysfunction** and erectile issues rather than stimulation of the pituitary gland or breast discharge. *Spironolactone* - **Spironolactone** acts as an **androgen receptor antagonist** and a weak inhibitor of androgen synthesis; it is not associated with elevated serum **prolactin**. - While it may cause **gynecomastia** through estrogenic-like effects, it does not typically induce **galactorrhea** or pituitary lactotroph changes. *Transdermal estradiol patches* - While **estrogen** can stimulate the growth of **lactotrophs**, transdermal delivery results in stable levels that are less likely to cause sudden, marked elevations in **prolactin** compared to high-dose oral therapy. - In the context of combined therapy, **Cyproterone acetate** is considered a more potent and specific pharmacological trigger for significant **prolactinemia** than standard doses of estradiol patches.

Q: A 32-year-old transgender woman on estradiol and spironolactone for 2 years wishes to undergo gender-affirming vaginoplasty. Pre-operative hormonal management should include:

Discontinuing estradiol 4 weeks before surgery due to VTE risk. ***Discontinuing estradiol 4 weeks before surgery due to VTE risk*** - **Estradiol** therapy is associated with an increased risk of **venous thromboembolism (VTE)**, which is further exacerbated by the immobility and tissue trauma of major surgery. - Current clinical guidelines recommend stopping **estrogen therapy** approximately **2 to 4 weeks** prior to gender-affirming surgery to mitigate the risk of perioperative blood clots. *Continuing current hormone regimen until surgery* - Maintaining high levels of exogenous **estrogen** during the perioperative period significantly increases the risk of **deep vein thrombosis (DVT)** and pulmonary embolism. - This practice is generally avoided unless the patient has specific risk factors that make the mental health impact of hormone withdrawal more dangerous than the VTE risk. *Adding progesterone to improve tissue quality* - There is no clinical evidence to support the claim that **progesterone** improves tissue quality or surgical outcomes for a **vaginoplasty**. - Adding progesterone may actually contribute to an increased **thrombotic risk** or other metabolic side effects without providing surgical benefits. *Increasing estradiol dose for better surgical outcomes* - Increasing the **estrogen** dose pre-operatively is contraindicated as it directly elevates the **pro-thrombotic state** of the patient. - Higher doses of hormones do not improve the technical success of the surgery and can lead to serious cardiovascular complications during recovery.

Q: A 24-year-old transgender man on testosterone therapy for 18 months presents with amenorrhea, deepening voice, and facial hair growth. Screening for which complication should be prioritized during follow-up?

Cervical cancer screening with Pap smear. ***Cervical cancer screening with Pap smear*** - **Transgender men** who have not undergone a total hysterectomy retain their **cervix** and remain at risk for **cervical cancer**, requiring screening as per standard guidelines. - **Testosterone therapy** can cause **vaginal atrophy**, which may lead to higher rates of unsatisfactory Pap results; however, it does not eliminate the need for monitoring. *Osteoporosis assessment with DEXA scan* - **Testosterone** is generally **bone-protective** as it is aromatized to estrogen, and bone mineral density often remains stable or increases during therapy. - **DEXA scans** are not routinely prioritized in young patients unless they are at high risk or have undergone **gonadectomy** without adequate hormone replacement. *Breast cancer screening with mammography* - While important if **chest reconstruction surgery** hasn't occurred, this patient is only 24; routine **mammography** usually begins at age 40 or 50. - Screening priority is based on **natal anatomy** present, and for a 24-year-old, cervical screening is the immediate age-appropriate intervention. *Endometrial hyperplasia evaluation* - Long-term **testosterone therapy** typically leads to **endometrial atrophy** rather than hyperplasia due to the suppression of the hypothalamic-pituitary-ovarian axis. - Routine ultrasound or biopsy for **endometrial hyperplasia** is not recommended in asymptomatic transgender men on testosterone.

Q: What is the mechanism by which GnRH analogs achieve pubertal suppression when used continuously in gender dysphoria management?

Down-regulation of pituitary GnRH receptors leading to decreased gonadotropin release. ***Down-regulation of pituitary GnRH receptors leading to decreased gonadotropin release*** - Continuous (non-pulsatile) administration of **GnRH analogs** leads to the **desensitization** and down-regulation of GnRH receptors on pituitary **gonadotrophs**. - This process inhibits the release of **LH and FSH**, resulting in the suppression of gonadal sex steroids to prepubertal levels, which halts **pubertal progression**. *Direct inhibition of gonadal steroidogenesis* - These drugs primarily act on the **anterior pituitary gland** rather than directly on the enzymatic pathways within the gonads. - The drop in steroid levels is a **secondary effect** of the lack of trophic stimulation from **gonadotropins**. *Competitive inhibition of GnRH receptors* - This refers to the mechanism of **GnRH antagonists** (e.g., Cetrorelix), which block receptors immediately without an initial flare. - **GnRH analogs** (agonists) first activate the receptor before causing the regulatory **down-regulation** that leads to suppression. *Upregulation of sex hormone-binding globulin* - While changes in **SHBG** can alter the levels of free hormones, it is not the primary mechanism of action for **pubertal blockers**. - The goal of GnRH analog therapy is to stop the **production** of sex hormones, not just manage their transport in the bloodstream.

Q: Why is spironolactone commonly used as an anti-androgen in transgender women undergoing feminizing hormone therapy?

It blocks androgen receptors and inhibits 5-alpha reductase. ***It blocks androgen receptors and inhibits 5-alpha reductase*** - **Spironolactone** acts primarily by **competitively blocking androgen receptors**, preventing testosterone and DHT from exerting their biological effects. - It also exhibits secondary activity by **inhibiting 5-alpha reductase**, the enzyme responsible for converting testosterone into the more potent **dihydrotestosterone (DHT)**. *It stimulates SHBG production* - **Sex Hormone-Binding Globulin (SHBG)** levels are typically increased by **oral estrogens**, not directly by spironolactone. - While higher SHBG levels decrease free testosterone, this is not the **primary mechanism** of action for spironolactone's anti-androgenic effects. *It increases estrogen receptor sensitivity* - Spironolactone does not have a known mechanism for increasing the **sensitivity or density** of estrogen receptors. - Its feminizing effects in hormone therapy are indirect, achieved by **reducing the interference** of male sex hormones at the cellular level. *It directly inhibits testosterone synthesis* - While spironolactone may have minor inhibitory effects on **17α-hydroxylase** and **17,20-desmolase**, its primary clinical efficacy is as a **receptor antagonist**. - Potent inhibition of synthesis is more characteristic of **GnRH agonists** or medications like ketoconazole, rather than the primary goal of spironolactone use.

Q: What is the recommended age for initiating puberty suppression therapy with GnRH analogs in adolescents with gender dysphoria according to international guidelines?

Tanner stage 2-3. ***Tanner stage 2-3*** - **GnRH analogs** are recommended to be initiated at **Tanner stage 2-3**, as this marks the onset of physical puberty where changes are still largely reversible. - This timing prevents the development of **secondary sexual characteristics** that cause significant distress, while allowing the adolescent more time for **psychological exploration**. *Tanner stage 1* - Initiating therapy at this stage is considered **premature** because the hypothalamic-pituitary-gonadal axis has not yet been activated. - Guidelines require the physical onset of puberty to be documented to confirm the **biological trajectory** of the adolescent. *After 18 years of age* - Waiting until adulthood is typically the standard for **gender-affirming surgeries**, not for **puberty suppression**. - Postponing treatment until 18 allows irreversible **endogenous puberty** to complete, which may exacerbate **gender dysphoria** and necessitate more invasive future procedures. *Tanner stage 4-5* - These stages represent late or completed puberty, where most **permanent physical changes** (such as voice deepening or breast development) have already occurred. - While **GnRH analogs** can still be used to stop menses or further virilization, the primary benefit of early **puberty suppression** is largely lost by this stage.

Q: Which hormone therapy is primarily used for feminizing gender-affirming hormone therapy in transgender women?

Estradiol with anti-androgen. ***Estradiol with anti-androgen*** - **Estradiol** (oral, transdermal, or injectable) is the primary hormone used to promote feminizing characteristics like **breast development** and female-pattern **fat redistribution**. - **Anti-androgens** (e.g., **spironolactone** or cyproterone acetate) are necessary to suppress **endogenous testosterone** levels to typical female ranges. *Testosterone cypionate* - This is an **androgen** used primarily for **masculinizing** hormone therapy in transgender men or for treating male hypogonadism. - Administration in transgender women would counteract feminization by promoting **virilization** and increasing muscle mass. *Progesterone alone* - Progesterone is occasionally added to regimens for its potential effect on **breast development** or libido, but it is not the primary feminizing agent. - Use of **progesterone alone** is insufficient to suppress testosterone or achieve significant feminization without **estradiol**. *Selective estrogen receptor modulators* - **SERMs** like tamoxifen or **raloxifene** act as estrogen agonists in some tissues and antagonists in others, which is inconsistent with goal of full feminization. - These are generally avoided in transgender women because they may inhibit **breast development**, which is a primary goal of feminizing therapy.

A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?

A 35-year-old transgender woman desires fertility preservation before starting feminizing hormone therapy. She has limited financial resources. Which option provides the best balance of efficacy, cost, and time efficiency?

A 28-year-old transgender man presents 6 months after initiating testosterone therapy with persistent vaginal bleeding despite amenorrhea for 4 months. Labs show testosterone 650 ng/dL and hemoglobin 9.2 g/dL. What is the most appropriate next step?

A 19-year-old transgender woman on feminizing hormone therapy presents with galactorrhea and serum prolactin of 85 ng/mL (normal <25). Which component of her therapy is most likely responsible?

A 32-year-old transgender woman on estradiol and spironolactone for 2 years wishes to undergo gender-affirming vaginoplasty. Pre-operative hormonal management should include:

A 24-year-old transgender man on testosterone therapy for 18 months presents with amenorrhea, deepening voice, and facial hair growth. Screening for which complication should be prioritized during follow-up?

What is the mechanism by which GnRH analogs achieve pubertal suppression when used continuously in gender dysphoria management?

Why is spironolactone commonly used as an anti-androgen in transgender women undergoing feminizing hormone therapy?

What is the recommended age for initiating puberty suppression therapy with GnRH analogs in adolescents with gender dysphoria according to international guidelines?

Q10

Which hormone therapy is primarily used for feminizing gender-affirming hormone therapy in transgender women?

Practice by Chapter

Gender Identity and Development

Practice Questions

Evaluation of Gender Dysphoria

Practice Questions

Hormonal Therapy for Transgender Patients

Practice Questions

Surgical Options in Gender Affirmation

Practice Questions

Reproductive Considerations for Transgender Patients

Practice Questions

Gynecologic Care of Transgender Men

Practice Questions

Primary Care for Transgender Women

Practice Questions

Mental Health Aspects of Gender-Affirming Care

Practice Questions

Ethical Considerations in Gender Care

Practice Questions

Long-term Follow-up and Monitoring

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free